#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1 .
1-1	0-1	1	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Introduction
2-1	4-16	Introduction	abstract	new	_	_

#Text=The liver is the central organ of lipid metabolism .
3-1	17-20	The	object[3]	new[3]	coref	3-4[4_3]
3-2	21-26	liver	object[3]	new[3]	_	_
3-3	27-29	is	_	_	_	_
3-4	30-33	the	object[4]	giv[4]	coref	4-7[10_4]
3-5	34-41	central	object[4]	giv[4]	_	_
3-6	42-47	organ	object[4]	giv[4]	_	_
3-7	48-50	of	object[4]	giv[4]	_	_
3-8	51-56	lipid	object[4]|object|abstract[6]	giv[4]|new|new[6]	coref|coref|coref|coref	12-7|19-7[129_6]|12-7|19-7[129_6]
3-9	57-67	metabolism	object[4]|abstract[6]	giv[4]|new[6]	_	_
3-10	68-69	.	_	_	_	_

#Text=Dietary fatty acids are transported to the liver and oxidized to produce as much energy as the hepatocyte needs .
4-1	70-77	Dietary	person|substance[9]	new|new[9]	coref|coref	5-1[13_9]|5-1[13_9]
4-2	78-83	fatty	abstract|substance[9]	new|new[9]	coref	5-3
4-3	84-89	acids	substance[9]	new[9]	_	_
4-4	90-93	are	_	_	_	_
4-5	94-105	transported	_	_	_	_
4-6	106-108	to	_	_	_	_
4-7	109-112	the	object[10]	giv[10]	coref	6-14[0_10]
4-8	113-118	liver	object[10]	giv[10]	_	_
4-9	119-122	and	_	_	_	_
4-10	123-131	oxidized	_	_	_	_
4-11	132-134	to	_	_	_	_
4-12	135-142	produce	_	_	_	_
4-13	143-145	as	_	_	_	_
4-14	146-150	much	_	_	_	_
4-15	151-157	energy	_	_	_	_
4-16	158-160	as	_	_	_	_
4-17	161-164	the	substance[11]	new[11]	coref	5-15[16_11]
4-18	165-175	hepatocyte	substance[11]	new[11]	_	_
4-19	176-181	needs	_	_	_	_
4-20	182-183	.	_	_	_	_

#Text=The excess fatty acids are converted to triglycerides ( TG ) and stored in the hepatocyte .
5-1	184-187	The	substance[13]	giv[13]	_	_
5-2	188-194	excess	substance[13]	giv[13]	_	_
5-3	195-200	fatty	abstract|substance[13]	giv|giv[13]	coref	7-18
5-4	201-206	acids	substance[13]	giv[13]	_	_
5-5	207-210	are	_	_	_	_
5-6	211-220	converted	_	_	_	_
5-7	221-223	to	_	_	_	_
5-8	224-237	triglycerides	substance	new	appos	5-10
5-9	238-239	(	_	_	_	_
5-10	240-242	TG	substance	giv	coref	6-5
5-11	243-244	)	_	_	_	_
5-12	245-248	and	_	_	_	_
5-13	249-255	stored	_	_	_	_
5-14	256-258	in	_	_	_	_
5-15	259-262	the	place[16]	giv[16]	_	_
5-16	263-273	hepatocyte	place[16]	giv[16]	_	_
5-17	274-275	.	_	_	_	_

#Text=When the amount of TG accounts for more than 5 % of the liver weight , the organ function is impaired , and this condition is known as fatty liver disease .
6-1	276-280	When	_	_	_	_
6-2	281-284	the	quantity[17]	new[17]	_	_
6-3	285-291	amount	quantity[17]	new[17]	_	_
6-4	292-294	of	quantity[17]	new[17]	_	_
6-5	295-297	TG	quantity[17]|substance	new[17]|giv	_	_
6-6	298-306	accounts	_	_	_	_
6-7	307-310	for	_	_	_	_
6-8	311-315	more	_	_	_	_
6-9	316-320	than	_	_	_	_
6-10	321-322	5	quantity[19]	new[19]	_	_
6-11	323-324	%	quantity[19]	new[19]	_	_
6-12	325-327	of	quantity[19]	new[19]	_	_
6-13	328-331	the	quantity[19]|abstract[21]	new[19]|new[21]	_	_
6-14	332-337	liver	quantity[19]|object|abstract[21]	new[19]|giv|new[21]	coref	6-18
6-15	338-344	weight	quantity[19]|abstract[21]	new[19]|new[21]	_	_
6-16	345-346	,	_	_	_	_
6-17	347-350	the	abstract[23]	new[23]	_	_
6-18	351-356	organ	object|abstract[23]	giv|new[23]	coref	6-30
6-19	357-365	function	abstract[23]	new[23]	_	_
6-20	366-368	is	_	_	_	_
6-21	369-377	impaired	_	_	_	_
6-22	378-379	,	_	_	_	_
6-23	380-383	and	_	_	_	_
6-24	384-388	this	abstract[24]	new[24]	_	_
6-25	389-398	condition	abstract[24]	new[24]	_	_
6-26	399-401	is	_	_	_	_
6-27	402-407	known	_	_	_	_
6-28	408-410	as	_	_	_	_
6-29	411-416	fatty	abstract[26]	new[26]	coref	11-1[57_26]
6-30	417-422	liver	object|abstract[26]	giv|new[26]	coref	7-12[30_0]
6-31	423-430	disease	abstract[26]	new[26]	_	_
6-32	431-432	.	_	_	_	_

#Text=Chronic alcohol intake has long been considered the major cause of alcoholic fatty liver , while non-alcoholic fatty liver has been shown to be unrelated to alcohol intake .
7-1	433-440	Chronic	event[28]	new[28]	coref	7-27[34_28]
7-2	441-448	alcohol	substance|event[28]	new|new[28]	coref	7-27
7-3	449-455	intake	event[28]	new[28]	_	_
7-4	456-459	has	_	_	_	_
7-5	460-464	long	_	_	_	_
7-6	465-469	been	_	_	_	_
7-7	470-480	considered	_	_	_	_
7-8	481-484	the	abstract[29]	new[29]	_	_
7-9	485-490	major	abstract[29]	new[29]	_	_
7-10	491-496	cause	abstract[29]	new[29]	_	_
7-11	497-499	of	abstract[29]	new[29]	_	_
7-12	500-509	alcoholic	abstract[29]|object[30]	new[29]|giv[30]	coref	7-17[32_30]
7-13	510-515	fatty	abstract[29]|object[30]	new[29]|giv[30]	_	_
7-14	516-521	liver	abstract[29]|object[30]	new[29]|giv[30]	_	_
7-15	522-523	,	_	_	_	_
7-16	524-529	while	_	_	_	_
7-17	530-543	non-alcoholic	object[32]	giv[32]	coref	8-4[36_32]
7-18	544-549	fatty	animal|object[32]	giv|giv[32]	_	_
7-19	550-555	liver	object[32]	giv[32]	_	_
7-20	556-559	has	_	_	_	_
7-21	560-564	been	_	_	_	_
7-22	565-570	shown	_	_	_	_
7-23	571-573	to	_	_	_	_
7-24	574-576	be	_	_	_	_
7-25	577-586	unrelated	_	_	_	_
7-26	587-589	to	_	_	_	_
7-27	590-597	alcohol	substance|event[34]	giv|giv[34]	coref|coref	8-13[40_34]|8-13[40_34]
7-28	598-604	intake	event[34]	giv[34]	_	_
7-29	605-606	.	_	_	_	_

#Text=The causes of non-alcoholic fatty liver are lifestyle habits , which include excessive dietary intake and lack of energy consumption .
8-1	607-610	The	abstract[35]	new[35]	coref	8-8[38_35]
8-2	611-617	causes	abstract[35]	new[35]	_	_
8-3	618-620	of	abstract[35]	new[35]	_	_
8-4	621-634	non-alcoholic	abstract[35]|object[36]	new[35]|giv[36]	coref	10-17[55_36]
8-5	635-640	fatty	abstract[35]|object[36]	new[35]|giv[36]	_	_
8-6	641-646	liver	abstract[35]|object[36]	new[35]|giv[36]	_	_
8-7	647-650	are	_	_	_	_
8-8	651-660	lifestyle	abstract|abstract[38]	new|giv[38]	coref|coref	9-8|9-8
8-9	661-667	habits	abstract[38]	giv[38]	_	_
8-10	668-669	,	_	_	_	_
8-11	670-675	which	_	_	_	_
8-12	676-683	include	_	_	_	_
8-13	684-693	excessive	event[40]	giv[40]	_	_
8-14	694-701	dietary	abstract|event[40]	new|giv[40]	_	_
8-15	702-708	intake	event[40]	giv[40]	_	_
8-16	709-712	and	_	_	_	_
8-17	713-717	lack	abstract[41]	new[41]	_	_
8-18	718-720	of	abstract[41]	new[41]	_	_
8-19	721-727	energy	abstract[41]|abstract[42]	new[41]|new[42]	ana	9-3[0_42]
8-20	728-739	consumption	abstract[41]|abstract[42]	new[41]|new[42]	_	_
8-21	740-741	.	_	_	_	_

#Text=Therefore , it is often accompanied by lifestyle diseases such as obesity , diabetes , and metabolic syndrome .
9-1	742-751	Therefore	_	_	_	_
9-2	752-753	,	_	_	_	_
9-3	754-756	it	abstract	giv	_	_
9-4	757-759	is	_	_	_	_
9-5	760-765	often	_	_	_	_
9-6	766-777	accompanied	_	_	_	_
9-7	778-780	by	_	_	_	_
9-8	781-790	lifestyle	abstract|abstract[45]	giv|new[45]	coref|coref	10-10[53_45]|10-10[53_45]
9-9	791-799	diseases	abstract[45]	new[45]	_	_
9-10	800-804	such	abstract[45]	new[45]	_	_
9-11	805-807	as	abstract[45]	new[45]	_	_
9-12	808-815	obesity	abstract[45]|abstract|abstract[47]	new[45]|new|new[47]	coref|coref|coref|coref	14-6|14-6[72_47]|14-6|14-6[72_47]
9-13	816-817	,	abstract[45]|abstract[47]	new[45]|new[47]	_	_
9-14	818-826	diabetes	abstract[45]|abstract[47]|abstract	new[45]|new[47]|new	coref	14-8
9-15	827-828	,	abstract[45]|abstract[47]	new[45]|new[47]	_	_
9-16	829-832	and	abstract[45]|abstract[47]	new[45]|new[47]	_	_
9-17	833-842	metabolic	abstract[45]|abstract[47]|person|abstract[50]	new[45]|new[47]|new|new[50]	_	_
9-18	843-851	syndrome	abstract[45]|abstract[47]|abstract[50]	new[45]|new[47]|new[50]	_	_
9-19	852-853	.	_	_	_	_

#Text=In recent times , with the growing incidence of these diseases , the attention paid to non-alcoholic fatty liver is gradually increasing .
10-1	854-856	In	_	_	_	_
10-2	857-863	recent	time[51]	new[51]	_	_
10-3	864-869	times	time[51]	new[51]	_	_
10-4	870-871	,	_	_	_	_
10-5	872-876	with	_	_	_	_
10-6	877-880	the	abstract[52]	new[52]	_	_
10-7	881-888	growing	abstract[52]	new[52]	_	_
10-8	889-898	incidence	abstract[52]	new[52]	_	_
10-9	899-901	of	abstract[52]	new[52]	_	_
10-10	902-907	these	abstract[52]|abstract[53]	new[52]|giv[53]	coref	27-23[190_53]
10-11	908-916	diseases	abstract[52]|abstract[53]	new[52]|giv[53]	_	_
10-12	917-918	,	_	_	_	_
10-13	919-922	the	abstract[54]	new[54]	_	_
10-14	923-932	attention	abstract[54]	new[54]	_	_
10-15	933-937	paid	_	_	_	_
10-16	938-940	to	_	_	_	_
10-17	941-954	non-alcoholic	object[55]	giv[55]	coref	11-3[0_55]
10-18	955-960	fatty	object[55]	giv[55]	_	_
10-19	961-966	liver	object[55]	giv[55]	_	_
10-20	967-969	is	_	_	_	_
10-21	970-979	gradually	_	_	_	_
10-22	980-990	increasing	_	_	_	_
10-23	991-992	.	_	_	_	_

#Text=Non-alcoholic fatty liver disease ( NAFLD ) shows various stages .
11-1	993-1006	Non-alcoholic	abstract[57]	giv[57]	appos	11-6[0_57]
11-2	1007-1012	fatty	abstract[57]	giv[57]	_	_
11-3	1013-1018	liver	object|abstract[57]	giv|giv[57]	coref	15-11[84_0]
11-4	1019-1026	disease	abstract[57]	giv[57]	_	_
11-5	1027-1028	(	_	_	_	_
11-6	1029-1034	NAFLD	abstract	giv	coref	14-18
11-7	1035-1036	)	_	_	_	_
11-8	1037-1042	shows	_	_	_	_
11-9	1043-1050	various	abstract[59]	new[59]	_	_
11-10	1051-1057	stages	abstract[59]	new[59]	_	_
11-11	1058-1059	.	_	_	_	_

#Text=Simple hepatic steatosis is characterized by lipid accumulation in hepatocytes .
12-1	1060-1066	Simple	abstract[61]	new[61]	_	_
12-2	1067-1074	hepatic	abstract|abstract[61]	new|new[61]	_	_
12-3	1075-1084	steatosis	abstract[61]	new[61]	_	_
12-4	1085-1087	is	_	_	_	_
12-5	1088-1101	characterized	_	_	_	_
12-6	1102-1104	by	_	_	_	_
12-7	1105-1110	lipid	abstract|abstract[63]	giv|new[63]	coref|coref|coref|coref	19-7|19-13[131_63]|19-7|19-13[131_63]
12-8	1111-1123	accumulation	abstract[63]	new[63]	_	_
12-9	1124-1126	in	abstract[63]	new[63]	_	_
12-10	1127-1138	hepatocytes	abstract[63]|object	new[63]|new	coref	19-16
12-11	1139-1140	.	_	_	_	_

#Text=Non-alcoholic steatohepatitis ( NASH ) can be further developed into cirrhosis and hepatocellular carcinoma .
13-1	1141-1154	Non-alcoholic	abstract[65]	new[65]	_	_
13-2	1155-1170	steatohepatitis	abstract[65]	new[65]	_	_
13-3	1171-1172	(	_	_	_	_
13-4	1173-1177	NASH	substance	new	_	_
13-5	1178-1179	)	_	_	_	_
13-6	1180-1183	can	_	_	_	_
13-7	1184-1186	be	_	_	_	_
13-8	1187-1194	further	_	_	_	_
13-9	1195-1204	developed	_	_	_	_
13-10	1205-1209	into	_	_	_	_
13-11	1210-1219	cirrhosis	abstract	new	_	_
13-12	1220-1223	and	_	_	_	_
13-13	1224-1238	hepatocellular	abstract|abstract[69]	new|new[69]	_	_
13-14	1239-1248	carcinoma	abstract[69]	new[69]	_	_
13-15	1249-1250	.	_	_	_	_

#Text=Although many factors such as obesity , diabetes , and inflammation have been implicated in relation to NAFLD in humans , the underlying mechanism of the development and progression of NAFLD remains unclear .
14-1	1251-1259	Although	_	_	_	_
14-2	1260-1264	many	abstract[70]	new[70]	coref	15-14[87_70]
14-3	1265-1272	factors	abstract[70]	new[70]	_	_
14-4	1273-1277	such	abstract[70]	new[70]	_	_
14-5	1278-1280	as	abstract[70]	new[70]	_	_
14-6	1281-1288	obesity	abstract[70]|abstract|abstract[72]	new[70]|giv|giv[72]	_	_
14-7	1289-1290	,	abstract[70]|abstract[72]	new[70]|giv[72]	_	_
14-8	1291-1299	diabetes	abstract[70]|abstract[72]|abstract	new[70]|giv[72]|giv	_	_
14-9	1300-1301	,	abstract[70]|abstract[72]	new[70]|giv[72]	_	_
14-10	1302-1305	and	abstract[70]|abstract[72]	new[70]|giv[72]	_	_
14-11	1306-1318	inflammation	abstract[70]|abstract[72]|abstract	new[70]|giv[72]|new	_	_
14-12	1319-1323	have	_	_	_	_
14-13	1324-1328	been	_	_	_	_
14-14	1329-1339	implicated	_	_	_	_
14-15	1340-1342	in	_	_	_	_
14-16	1343-1351	relation	abstract[75]	new[75]	_	_
14-17	1352-1354	to	abstract[75]	new[75]	_	_
14-18	1355-1360	NAFLD	abstract[75]|abstract	new[75]|giv	coref	14-31
14-19	1361-1363	in	_	_	_	_
14-20	1364-1370	humans	person	new	_	_
14-21	1371-1372	,	_	_	_	_
14-22	1373-1376	the	abstract[78]	new[78]	_	_
14-23	1377-1387	underlying	abstract[78]	new[78]	_	_
14-24	1388-1397	mechanism	abstract[78]	new[78]	_	_
14-25	1398-1400	of	abstract[78]	new[78]	_	_
14-26	1401-1404	the	abstract[78]|event[79]	new[78]|new[79]	_	_
14-27	1405-1416	development	abstract[78]|event[79]	new[78]|new[79]	_	_
14-28	1417-1420	and	abstract[78]	new[78]	_	_
14-29	1421-1432	progression	abstract[78]|event[80]	new[78]|new[80]	_	_
14-30	1433-1435	of	abstract[78]|event[80]	new[78]|new[80]	_	_
14-31	1436-1441	NAFLD	abstract[78]|event[80]|abstract	new[78]|new[80]|giv	coref	16-27
14-32	1442-1449	remains	_	_	_	_
14-33	1450-1457	unclear	_	_	_	_
14-34	1458-1459	.	_	_	_	_

#Text=When free fatty acid ( FFA ) is overloaded in the body , FFA uptake factors such as cluster of differentiation 36 ( CD36 ) and fatty acid transport proteins ( FATPs ) are significantly up-regulated , and then excessive FFA is accepted into the liver , gradually accumulating .
15-1	1460-1464	When	_	_	_	_
15-2	1465-1469	free	substance[82]	new[82]	coref	15-28[0_82]
15-3	1470-1475	fatty	substance[82]	new[82]	_	_
15-4	1476-1480	acid	substance[82]	new[82]	_	_
15-5	1481-1482	(	_	_	_	_
15-6	1483-1486	FFA	abstract	new	coref	15-14
15-7	1487-1488	)	_	_	_	_
15-8	1489-1491	is	_	_	_	_
15-9	1492-1502	overloaded	_	_	_	_
15-10	1503-1505	in	_	_	_	_
15-11	1506-1509	the	object[84]	giv[84]	coref	15-45[96_84]
15-12	1510-1514	body	object[84]	giv[84]	_	_
15-13	1515-1516	,	_	_	_	_
15-14	1517-1520	FFA	abstract|abstract[87]	giv|giv[87]	coref|coref|coref|coref	15-40[95_0]|21-18[143_87]|15-40[95_0]|21-18[143_87]
15-15	1521-1527	uptake	abstract|abstract[87]	new|giv[87]	_	_
15-16	1528-1535	factors	abstract[87]	giv[87]	_	_
15-17	1536-1540	such	abstract[87]	giv[87]	_	_
15-18	1541-1543	as	abstract[87]	giv[87]	_	_
15-19	1544-1551	cluster	abstract[87]|abstract[88]	giv[87]|new[88]	_	_
15-20	1552-1554	of	abstract[87]|abstract[88]	giv[87]|new[88]	_	_
15-21	1555-1570	differentiation	abstract[87]|abstract[88]|abstract[89]	giv[87]|new[88]|new[89]	appos	15-24[0_89]
15-22	1571-1573	36	abstract[87]|abstract[88]|abstract[89]	giv[87]|new[88]|new[89]	_	_
15-23	1574-1575	(	abstract[87]	giv[87]	_	_
15-24	1576-1580	CD36	abstract[87]|abstract	giv[87]|giv	coref	17-12[109_0]
15-25	1581-1582	)	abstract[87]	giv[87]	_	_
15-26	1583-1586	and	abstract[87]	giv[87]	_	_
15-27	1587-1592	fatty	abstract[87]|substance[93]	giv[87]|new[93]	_	_
15-28	1593-1597	acid	abstract[87]|substance|substance[93]	giv[87]|giv|new[93]	coref	16-6[98_0]
15-29	1598-1607	transport	abstract[87]|abstract|substance[93]	giv[87]|new|new[93]	_	_
15-30	1608-1616	proteins	abstract[87]|substance[93]	giv[87]|new[93]	_	_
15-31	1617-1618	(	_	_	_	_
15-32	1619-1624	FATPs	object	new	_	_
15-33	1625-1626	)	_	_	_	_
15-34	1627-1630	are	_	_	_	_
15-35	1631-1644	significantly	_	_	_	_
15-36	1645-1657	up-regulated	_	_	_	_
15-37	1658-1659	,	_	_	_	_
15-38	1660-1663	and	_	_	_	_
15-39	1664-1668	then	_	_	_	_
15-40	1669-1678	excessive	abstract[95]	giv[95]	_	_
15-41	1679-1682	FFA	abstract[95]	giv[95]	_	_
15-42	1683-1685	is	_	_	_	_
15-43	1686-1694	accepted	_	_	_	_
15-44	1695-1699	into	_	_	_	_
15-45	1700-1703	the	object[96]	giv[96]	coref	18-17[122_96]
15-46	1704-1709	liver	object[96]	giv[96]	_	_
15-47	1710-1711	,	_	_	_	_
15-48	1712-1721	gradually	_	_	_	_
15-49	1722-1734	accumulating	_	_	_	_
15-50	1735-1736	.	_	_	_	_

#Text=According to previous studies , palmitic acid and high-fat ( HF ) diet markedly increased CD36 expression , which is closely associated with the development of NAFLD .
16-1	1737-1746	According	_	_	_	_
16-2	1747-1749	to	_	_	_	_
16-3	1750-1758	previous	event[97]	new[97]	coref	17-3[106_97]
16-4	1759-1766	studies	event[97]	new[97]	_	_
16-5	1767-1768	,	_	_	_	_
16-6	1769-1777	palmitic	substance[98]	giv[98]	coref	17-9[0_98]
16-7	1778-1782	acid	substance[98]	giv[98]	_	_
16-8	1783-1786	and	_	_	_	_
16-9	1787-1795	high-fat	object	new	_	_
16-10	1796-1797	(	_	_	_	_
16-11	1798-1800	HF	substance	new	coref	22-7
16-12	1801-1802	)	_	_	_	_
16-13	1803-1807	diet	event	new	coref	22-6[156_0]
16-14	1808-1816	markedly	abstract[103]	new[103]	coref	21-15[141_103]
16-15	1817-1826	increased	abstract[103]	new[103]	_	_
16-16	1827-1831	CD36	person|abstract[103]	new|new[103]	_	_
16-17	1832-1842	expression	abstract[103]	new[103]	_	_
16-18	1843-1844	,	_	_	_	_
16-19	1845-1850	which	_	_	_	_
16-20	1851-1853	is	_	_	_	_
16-21	1854-1861	closely	_	_	_	_
16-22	1862-1872	associated	_	_	_	_
16-23	1873-1877	with	_	_	_	_
16-24	1878-1881	the	event[104]	new[104]	_	_
16-25	1882-1893	development	event[104]	new[104]	_	_
16-26	1894-1896	of	event[104]	new[104]	_	_
16-27	1897-1902	NAFLD	event[104]|abstract	new[104]|giv	coref	20-8
16-28	1903-1904	.	_	_	_	_

#Text=Furthermore , several studies have indicated that fatty acid overflow by activated CD36 subsequently produced a higher level of reactive oxygen species ( ROS ) , which could be linked to oxidative stress .
17-1	1905-1916	Furthermore	_	_	_	_
17-2	1917-1918	,	_	_	_	_
17-3	1919-1926	several	event[106]	giv[106]	_	_
17-4	1927-1934	studies	event[106]	giv[106]	_	_
17-5	1935-1939	have	_	_	_	_
17-6	1940-1949	indicated	_	_	_	_
17-7	1950-1954	that	_	_	_	_
17-8	1955-1960	fatty	abstract[108]	new[108]	_	_
17-9	1961-1965	acid	substance|abstract[108]	giv|new[108]	coref	21-30
17-10	1966-1974	overflow	abstract[108]	new[108]	_	_
17-11	1975-1977	by	abstract[108]	new[108]	_	_
17-12	1978-1987	activated	abstract[108]|abstract[109]	new[108]|giv[109]	_	_
17-13	1988-1992	CD36	abstract[108]|abstract[109]	new[108]|giv[109]	_	_
17-14	1993-2005	subsequently	_	_	_	_
17-15	2006-2014	produced	_	_	_	_
17-16	2015-2016	a	quantity[110]	new[110]	_	_
17-17	2017-2023	higher	quantity[110]	new[110]	_	_
17-18	2024-2029	level	quantity[110]	new[110]	_	_
17-19	2030-2032	of	quantity[110]	new[110]	_	_
17-20	2033-2041	reactive	quantity[110]|abstract[112]	new[110]|new[112]	_	_
17-21	2042-2048	oxygen	quantity[110]|substance|abstract[112]	new[110]|new|new[112]	_	_
17-22	2049-2056	species	quantity[110]|abstract[112]	new[110]|new[112]	_	_
17-23	2057-2058	(	_	_	_	_
17-24	2059-2062	ROS	substance	new	coref	18-10
17-25	2063-2064	)	_	_	_	_
17-26	2065-2066	,	_	_	_	_
17-27	2067-2072	which	_	_	_	_
17-28	2073-2078	could	_	_	_	_
17-29	2079-2081	be	_	_	_	_
17-30	2082-2088	linked	_	_	_	_
17-31	2089-2091	to	_	_	_	_
17-32	2092-2101	oxidative	abstract|abstract[115]	new|new[115]	coref|coref|coref|coref	18-1[116_115]|21-9|18-1[116_115]|21-9
17-33	2102-2108	stress	abstract[115]	new[115]	_	_
17-34	2109-2110	.	_	_	_	_

#Text=Oxidative stress is the imbalance between the production of ROS and the activation of antioxidants in the body and results in several metabolic disorders .
18-1	2111-2120	Oxidative	abstract[116]	giv[116]	coref	18-4[117_116]
18-2	2121-2127	stress	abstract[116]	giv[116]	_	_
18-3	2128-2130	is	_	_	_	_
18-4	2131-2134	the	abstract[117]	giv[117]	coref	20-10[135_117]
18-5	2135-2144	imbalance	abstract[117]	giv[117]	_	_
18-6	2145-2152	between	abstract[117]	giv[117]	_	_
18-7	2153-2156	the	abstract[117]|abstract[118]	giv[117]|new[118]	coref	22-31[165_118]
18-8	2157-2167	production	abstract[117]|abstract[118]	giv[117]|new[118]	_	_
18-9	2168-2170	of	abstract[117]|abstract[118]	giv[117]|new[118]	_	_
18-10	2171-2174	ROS	abstract[117]|abstract[118]|substance	giv[117]|new[118]|giv	coref	22-34
18-11	2175-2178	and	abstract[117]	giv[117]	_	_
18-12	2179-2182	the	abstract[117]|abstract[120]	giv[117]|new[120]	ana	19-1[0_120]
18-13	2183-2193	activation	abstract[117]|abstract[120]	giv[117]|new[120]	_	_
18-14	2194-2196	of	abstract[117]|abstract[120]	giv[117]|new[120]	_	_
18-15	2197-2209	antioxidants	abstract[117]|abstract[120]|substance[121]	giv[117]|new[120]|new[121]	coref	27-5[186_121]
18-16	2210-2212	in	abstract[117]|abstract[120]|substance[121]	giv[117]|new[120]|new[121]	_	_
18-17	2213-2216	the	abstract[117]|abstract[120]|substance[121]|object[122]	giv[117]|new[120]|new[121]|giv[122]	coref	23-23[174_122]
18-18	2217-2221	body	abstract[117]|abstract[120]|substance[121]|object[122]	giv[117]|new[120]|new[121]|giv[122]	_	_
18-19	2222-2225	and	abstract[117]|abstract[120]|substance[121]|object[122]	giv[117]|new[120]|new[121]|giv[122]	_	_
18-20	2226-2233	results	abstract[117]|abstract[120]|substance[121]|object[122]|abstract[123]	giv[117]|new[120]|new[121]|giv[122]|new[123]	_	_
18-21	2234-2236	in	abstract[117]|abstract[120]|substance[121]|object[122]|abstract[123]	giv[117]|new[120]|new[121]|giv[122]|new[123]	_	_
18-22	2237-2244	several	abstract[117]|abstract[120]|substance[121]|object[122]|abstract[123]|abstract[125]	giv[117]|new[120]|new[121]|giv[122]|new[123]|new[125]	coref	23-3[168_125]
18-23	2245-2254	metabolic	abstract[117]|abstract[120]|substance[121]|object[122]|abstract[123]|abstract|abstract[125]	giv[117]|new[120]|new[121]|giv[122]|new[123]|new|new[125]	coref	23-3
18-24	2255-2264	disorders	abstract[117]|abstract[120]|substance[121]|object[122]|abstract[123]|abstract[125]	giv[117]|new[120]|new[121]|giv[122]|new[123]|new[125]	_	_
18-25	2265-2266	.	_	_	_	_

#Text=It particularly produces a disturbance in lipid metabolism , eventually leading to lipid accumulation in hepatocytes .
19-1	2267-2269	It	abstract	giv	_	_
19-2	2270-2282	particularly	_	_	_	_
19-3	2283-2291	produces	_	_	_	_
19-4	2292-2293	a	abstract[127]	new[127]	_	_
19-5	2294-2305	disturbance	abstract[127]	new[127]	_	_
19-6	2306-2308	in	abstract[127]	new[127]	_	_
19-7	2309-2314	lipid	abstract[127]|object|abstract[129]	new[127]|giv|giv[129]	coref|coref	19-13|19-13
19-8	2315-2325	metabolism	abstract[127]|abstract[129]	new[127]|giv[129]	_	_
19-9	2326-2327	,	_	_	_	_
19-10	2328-2338	eventually	_	_	_	_
19-11	2339-2346	leading	_	_	_	_
19-12	2347-2349	to	_	_	_	_
19-13	2350-2355	lipid	abstract|abstract[131]	giv|giv[131]	coref|coref|coref|coref	29-8|29-8[206_131]|29-8|29-8[206_131]
19-14	2356-2368	accumulation	abstract[131]	giv[131]	_	_
19-15	2369-2371	in	abstract[131]	giv[131]	_	_
19-16	2372-2383	hepatocytes	abstract[131]|object	giv[131]|giv	coref	21-12
19-17	2384-2385	.	_	_	_	_

#Text=Of the several existing pathogenic mechanisms of NAFLD , oxidative stress is considered a major contributor .
20-1	2386-2388	Of	_	_	_	_
20-2	2389-2392	the	abstract[133]	new[133]	_	_
20-3	2393-2400	several	abstract[133]	new[133]	_	_
20-4	2401-2409	existing	abstract[133]	new[133]	_	_
20-5	2410-2420	pathogenic	abstract[133]	new[133]	_	_
20-6	2421-2431	mechanisms	abstract[133]	new[133]	_	_
20-7	2432-2434	of	abstract[133]	new[133]	_	_
20-8	2435-2440	NAFLD	abstract[133]|substance	new[133]|giv	_	_
20-9	2441-2442	,	_	_	_	_
20-10	2443-2452	oxidative	abstract[135]	giv[135]	coref	21-7[139_135]
20-11	2453-2459	stress	abstract[135]	giv[135]	_	_
20-12	2460-2462	is	_	_	_	_
20-13	2463-2473	considered	_	_	_	_
20-14	2474-2475	a	abstract[136]	new[136]	_	_
20-15	2476-2481	major	abstract[136]	new[136]	_	_
20-16	2482-2493	contributor	abstract[136]	new[136]	_	_
20-17	2494-2495	.	_	_	_	_

#Text=According to a previous study , uric acid-induced oxidative stress in hepatocytes significantly elevated the expression of lipogenesis factors such as acetyl-coenzyme A carboxylase ( ACC ) , fatty acid synthase ( FAS ) , and sterol regulatory element-binding protein-1c ( SREBP-1c ) .
21-1	2496-2505	According	_	_	_	_
21-2	2506-2508	to	_	_	_	_
21-3	2509-2510	a	abstract[137]	new[137]	coref	22-1[154_137]
21-4	2511-2519	previous	abstract[137]	new[137]	_	_
21-5	2520-2525	study	abstract[137]	new[137]	_	_
21-6	2526-2527	,	_	_	_	_
21-7	2528-2532	uric	abstract[139]	giv[139]	coref	23-7[169_139]
21-8	2533-2545	acid-induced	abstract[139]	giv[139]	_	_
21-9	2546-2555	oxidative	abstract|abstract[139]	giv|giv[139]	coref	29-11
21-10	2556-2562	stress	abstract[139]	giv[139]	_	_
21-11	2563-2565	in	abstract[139]	giv[139]	_	_
21-12	2566-2577	hepatocytes	abstract[139]|place	giv[139]|giv	_	_
21-13	2578-2591	significantly	_	_	_	_
21-14	2592-2600	elevated	_	_	_	_
21-15	2601-2604	the	abstract[141]	giv[141]	_	_
21-16	2605-2615	expression	abstract[141]	giv[141]	_	_
21-17	2616-2618	of	abstract[141]	giv[141]	_	_
21-18	2619-2630	lipogenesis	abstract[141]|abstract|abstract[143]	giv[141]|new|giv[143]	_	_
21-19	2631-2638	factors	abstract[141]|abstract[143]	giv[141]|giv[143]	_	_
21-20	2639-2643	such	abstract[141]	giv[141]	_	_
21-21	2644-2646	as	abstract[141]	giv[141]	_	_
21-22	2647-2662	acetyl-coenzyme	abstract[141]|abstract	giv[141]|new	appos	21-23[145_0]
21-23	2663-2664	A	object[145]	giv[145]	appos	21-26[0_145]
21-24	2665-2676	carboxylase	object[145]	giv[145]	_	_
21-25	2677-2678	(	_	_	_	_
21-26	2679-2682	ACC	object	giv	_	_
21-27	2683-2684	)	_	_	_	_
21-28	2685-2686	,	_	_	_	_
21-29	2687-2692	fatty	abstract[148]	new[148]	appos	21-33[0_148]
21-30	2693-2697	acid	substance|abstract[148]	giv|new[148]	_	_
21-31	2698-2706	synthase	abstract[148]	new[148]	_	_
21-32	2707-2708	(	_	_	_	_
21-33	2709-2712	FAS	abstract	giv	_	_
21-34	2713-2714	)	_	_	_	_
21-35	2715-2716	,	_	_	_	_
21-36	2717-2720	and	_	_	_	_
21-37	2721-2727	sterol	abstract|abstract[152]	new|new[152]	_	_
21-38	2728-2738	regulatory	abstract[152]	new[152]	_	_
21-39	2739-2754	element-binding	abstract|abstract[152]	new|new[152]	_	_
21-40	2755-2765	protein-1c	abstract[152]	new[152]	_	_
21-41	2766-2767	(	_	_	_	_
21-42	2768-2776	SREBP-1c	abstract	new	_	_
21-43	2777-2778	)	_	_	_	_
21-44	2779-2780	.	_	_	_	_

#Text=Another study has shown that an HF diet destroyed the antioxidant defense system by decreasing superoxide dismutase ( SOD ) and catalase ( CAT ) activities , and markedly increased the production of ROS .
22-1	2781-2788	Another	abstract[154]	giv[154]	coref	28-4[195_154]
22-2	2789-2794	study	abstract[154]	giv[154]	_	_
22-3	2795-2798	has	_	_	_	_
22-4	2799-2804	shown	_	_	_	_
22-5	2805-2809	that	_	_	_	_
22-6	2810-2812	an	event[156]	giv[156]	_	_
22-7	2813-2815	HF	animal|event[156]	giv|giv[156]	_	_
22-8	2816-2820	diet	event[156]	giv[156]	_	_
22-9	2821-2830	destroyed	_	_	_	_
22-10	2831-2834	the	abstract[158]	new[158]	_	_
22-11	2835-2846	antioxidant	abstract[158]	new[158]	_	_
22-12	2847-2854	defense	abstract|abstract[158]	new|new[158]	_	_
22-13	2855-2861	system	abstract[158]	new[158]	_	_
22-14	2862-2864	by	_	_	_	_
22-15	2865-2875	decreasing	_	_	_	_
22-16	2876-2886	superoxide	substance|abstract[160]	new|new[160]	_	_
22-17	2887-2896	dismutase	abstract[160]	new[160]	_	_
22-18	2897-2898	(	_	_	_	_
22-19	2899-2902	SOD	substance	new	_	_
22-20	2903-2904	)	_	_	_	_
22-21	2905-2908	and	_	_	_	_
22-22	2909-2917	catalase	object	new	appos	22-24
22-23	2918-2919	(	_	_	_	_
22-24	2920-2923	CAT	object	giv	_	_
22-25	2924-2925	)	_	_	_	_
22-26	2926-2936	activities	abstract	new	_	_
22-27	2937-2938	,	_	_	_	_
22-28	2939-2942	and	_	_	_	_
22-29	2943-2951	markedly	_	_	_	_
22-30	2952-2961	increased	_	_	_	_
22-31	2962-2965	the	abstract[165]	giv[165]	coref	23-16[172_165]
22-32	2966-2976	production	abstract[165]	giv[165]	_	_
22-33	2977-2979	of	abstract[165]	giv[165]	_	_
22-34	2980-2983	ROS	abstract[165]|substance	giv[165]|giv	coref	23-16
22-35	2984-2985	.	_	_	_	_

#Text=To prevent metabolic disorders due to oxidative stress , antioxidative capability that suppresses or eliminates ROS production plays an important role in the body .
23-1	2986-2988	To	_	_	_	_
23-2	2989-2996	prevent	_	_	_	_
23-3	2997-3006	metabolic	abstract|abstract[168]	giv|giv[168]	_	_
23-4	3007-3016	disorders	abstract[168]	giv[168]	_	_
23-5	3017-3020	due	abstract[168]	giv[168]	_	_
23-6	3021-3023	to	_	_	_	_
23-7	3024-3033	oxidative	abstract[169]	giv[169]	coref	29-11[208_169]
23-8	3034-3040	stress	abstract[169]	giv[169]	_	_
23-9	3041-3042	,	_	_	_	_
23-10	3043-3056	antioxidative	abstract[170]	new[170]	_	_
23-11	3057-3067	capability	abstract[170]	new[170]	_	_
23-12	3068-3072	that	_	_	_	_
23-13	3073-3083	suppresses	_	_	_	_
23-14	3084-3086	or	_	_	_	_
23-15	3087-3097	eliminates	_	_	_	_
23-16	3098-3101	ROS	substance|abstract[172]	giv|giv[172]	coref|coref	24-14|24-14
23-17	3102-3112	production	abstract[172]	giv[172]	_	_
23-18	3113-3118	plays	_	_	_	_
23-19	3119-3121	an	abstract[173]	new[173]	_	_
23-20	3122-3131	important	abstract[173]	new[173]	_	_
23-21	3132-3136	role	abstract[173]	new[173]	_	_
23-22	3137-3139	in	abstract[173]	new[173]	_	_
23-23	3140-3143	the	abstract[173]|object[174]	new[173]|giv[174]	coref	27-27[0_174]
23-24	3144-3148	body	abstract[173]|object[174]	new[173]|giv[174]	_	_
23-25	3149-3150	.	_	_	_	_

#Text=Plants contain a variety of phytochemicals that have antioxidant ability to effectively remove ROS .
24-1	3151-3157	Plants	plant	new	_	_
24-2	3158-3165	contain	_	_	_	_
24-3	3166-3167	a	abstract[176]	new[176]	_	_
24-4	3168-3175	variety	abstract[176]	new[176]	_	_
24-5	3176-3178	of	abstract[176]	new[176]	_	_
24-6	3179-3193	phytochemicals	abstract[176]|substance	new[176]|new	_	_
24-7	3194-3198	that	_	_	_	_
24-8	3199-3203	have	_	_	_	_
24-9	3204-3215	antioxidant	person|abstract[179]	new|new[179]	_	_
24-10	3216-3223	ability	abstract[179]	new[179]	_	_
24-11	3224-3226	to	_	_	_	_
24-12	3227-3238	effectively	_	_	_	_
24-13	3239-3245	remove	_	_	_	_
24-14	3246-3249	ROS	substance	giv	_	_
24-15	3250-3251	.	_	_	_	_

#Text=Curcuma longa
25-1	3252-3259	Curcuma	_	_	_	_
25-2	3260-3265	longa	_	_	_	_

#Text=L. is a flowering plant of the ginger family ( Zingiberaceae ) .
26-1	3266-3268	L.	person	new	_	_
26-2	3269-3271	is	_	_	_	_
26-3	3272-3273	a	plant[182]	new[182]	_	_
26-4	3274-3283	flowering	plant[182]	new[182]	_	_
26-5	3284-3289	plant	plant[182]	new[182]	_	_
26-6	3290-3292	of	plant[182]	new[182]	_	_
26-7	3293-3296	the	plant[182]|person[183]	new[182]|new[183]	_	_
26-8	3297-3303	ginger	plant[182]|person[183]	new[182]|new[183]	_	_
26-9	3304-3310	family	plant[182]|person[183]	new[182]|new[183]	_	_
26-10	3311-3312	(	_	_	_	_
26-11	3313-3326	Zingiberaceae	plant	new	_	_
26-12	3327-3328	)	_	_	_	_
26-13	3329-3330	.	_	_	_	_

#Text=As C. longa possesses natural antioxidants , which leads to free radical scavenging potential , it has been widely used to prevent many diseases , including liver injury .
27-1	3331-3333	As	_	_	_	_
27-2	3334-3336	C.	person	new	coref	28-24
27-3	3337-3342	longa	_	_	_	_
27-4	3343-3352	possesses	_	_	_	_
27-5	3353-3360	natural	substance[186]	giv[186]	_	_
27-6	3361-3373	antioxidants	substance[186]	giv[186]	_	_
27-7	3374-3375	,	_	_	_	_
27-8	3376-3381	which	_	_	_	_
27-9	3382-3387	leads	_	_	_	_
27-10	3388-3390	to	_	_	_	_
27-11	3391-3395	free	abstract[188]	new[188]	ana	27-16[0_188]
27-12	3396-3403	radical	abstract[188]	new[188]	_	_
27-13	3404-3414	scavenging	abstract|abstract[188]	new|new[188]	_	_
27-14	3415-3424	potential	abstract[188]	new[188]	_	_
27-15	3425-3426	,	_	_	_	_
27-16	3427-3429	it	abstract	giv	_	_
27-17	3430-3433	has	_	_	_	_
27-18	3434-3438	been	_	_	_	_
27-19	3439-3445	widely	_	_	_	_
27-20	3446-3450	used	_	_	_	_
27-21	3451-3453	to	_	_	_	_
27-22	3454-3461	prevent	_	_	_	_
27-23	3462-3466	many	abstract[190]	giv[190]	_	_
27-24	3467-3475	diseases	abstract[190]	giv[190]	_	_
27-25	3476-3477	,	abstract[190]	giv[190]	_	_
27-26	3478-3487	including	abstract[190]	giv[190]	_	_
27-27	3488-3493	liver	abstract[190]|object|event[192]	giv[190]|giv|new[192]	coref|coref	28-30[202_0]|28-30[202_0]
27-28	3494-3500	injury	abstract[190]|event[192]	giv[190]|new[192]	_	_
27-29	3501-3502	.	_	_	_	_

#Text=The aim of our study was to investigate in vitro and in vivo protective effects of hot water extract ( CLW ) from C. longa on the development of fatty liver .
28-1	3503-3506	The	abstract[193]	new[193]	_	_
28-2	3507-3510	aim	abstract[193]	new[193]	_	_
28-3	3511-3513	of	abstract[193]	new[193]	_	_
28-4	3514-3517	our	abstract[193]|person|abstract[195]	new[193]|acc|giv[195]	_	_
28-5	3518-3523	study	abstract[193]|abstract[195]	new[193]|giv[195]	_	_
28-6	3524-3527	was	_	_	_	_
28-7	3528-3530	to	_	_	_	_
28-8	3531-3542	investigate	_	_	_	_
28-9	3543-3545	in	_	_	_	_
28-10	3546-3551	vitro	_	_	_	_
28-11	3552-3555	and	_	_	_	_
28-12	3556-3558	in	_	_	_	_
28-13	3559-3563	vivo	abstract[196]	new[196]	_	_
28-14	3564-3574	protective	abstract[196]	new[196]	_	_
28-15	3575-3582	effects	abstract[196]	new[196]	_	_
28-16	3583-3585	of	abstract[196]	new[196]	_	_
28-17	3586-3589	hot	abstract[196]|substance[198]	new[196]|new[198]	appos	28-21[0_198]
28-18	3590-3595	water	abstract[196]|substance|substance[198]	new[196]|new|new[198]	_	_
28-19	3596-3603	extract	abstract[196]|substance[198]	new[196]|new[198]	_	_
28-20	3604-3605	(	_	_	_	_
28-21	3606-3609	CLW	substance	giv	_	_
28-22	3610-3611	)	_	_	_	_
28-23	3612-3616	from	_	_	_	_
28-24	3617-3619	C.	person	giv	_	_
28-25	3620-3625	longa	_	_	_	_
28-26	3626-3628	on	_	_	_	_
28-27	3629-3632	the	abstract[201]	new[201]	_	_
28-28	3633-3644	development	abstract[201]	new[201]	_	_
28-29	3645-3647	of	abstract[201]	new[201]	_	_
28-30	3648-3653	fatty	abstract[201]|object[202]	new[201]|giv[202]	coref	29-15[0_202]
28-31	3654-3659	liver	abstract[201]|object[202]	new[201]|giv[202]	_	_
28-32	3660-3661	.	_	_	_	_

#Text=Furthermore , the mode of action against lipid accumulation and oxidative stress in non-alcoholic liver damage was determined .
29-1	3662-3673	Furthermore	_	_	_	_
29-2	3674-3675	,	_	_	_	_
29-3	3676-3679	the	abstract[203]	new[203]	_	_
29-4	3680-3684	mode	abstract[203]	new[203]	_	_
29-5	3685-3687	of	abstract[203]	new[203]	_	_
29-6	3688-3694	action	abstract[203]|abstract[204]	new[203]|new[204]	_	_
29-7	3695-3702	against	abstract[203]|abstract[204]	new[203]|new[204]	_	_
29-8	3703-3708	lipid	abstract[203]|abstract[204]|abstract|abstract[206]	new[203]|new[204]|giv|giv[206]	_	_
29-9	3709-3721	accumulation	abstract[203]|abstract[204]|abstract[206]	new[203]|new[204]|giv[206]	_	_
29-10	3722-3725	and	abstract[203]|abstract[204]	new[203]|new[204]	_	_
29-11	3726-3735	oxidative	abstract[203]|abstract[204]|abstract|abstract[208]	new[203]|new[204]|giv|giv[208]	_	_
29-12	3736-3742	stress	abstract[203]|abstract[204]|abstract[208]	new[203]|new[204]|giv[208]	_	_
29-13	3743-3745	in	abstract[203]	new[203]	_	_
29-14	3746-3759	non-alcoholic	abstract[203]|abstract[210]	new[203]|new[210]	_	_
29-15	3760-3765	liver	abstract[203]|object|abstract[210]	new[203]|giv|new[210]	_	_
29-16	3766-3772	damage	abstract[203]|abstract[210]	new[203]|new[210]	_	_
29-17	3773-3776	was	_	_	_	_
29-18	3777-3787	determined	_	_	_	_
29-19	3788-3789	.	_	_	_	_
